Harvard Bioscience Reports 8% Revenue Growth in Q3 and Outlines Q4 EBITDA Guidance
Harvard Bioscience (HBIO) reported a solid third quarter, highlighted by an 8% increase in revenue. Management attributed this growth to strong double-digit momentum within specific product segments, including organoids and fluidics. Looking ahead, the company provided adjusted EBITDA guidance for the fourth quarter in the range of $3.8 million to $4.2 million. Additionally, the company is executing 'Project Viking,' a strategic initiative aimed at achieving $3 million in annual savings by 2027.
Tickers: $HBIO
Topics: earnings fluidics organoids revenue growth